$1.90
+0.04 (+2.15%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where TVRD is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional
Held by 4 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, AQR CAPITAL MANAGEMENT LLC, Qube Research & Technologies Ltd) · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular CarcinomaNCT05440708Incidence of Adverse Events (AE)Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: TTI-101, Pembrolizumab, Atezolizumab, Bevacizumab | Hepatocellular Carcinoma | 193 | 2027-02-01 | in 166 d | 2026-04-27 |
| Study of TTI-101 in Participants With Idiopathic Pulmonary FibrosisNCT05671835Number of Participants with an Adverse Event (AE)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: TTI-101, Placebo | Idiopathic Pulmonary Fibrosis | 100 | 2025-08-14actual | — | 2026-08-13 |
| Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced CancersNCT03195699Maximum Tolerated Dose of TTI-101Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: TTI-101, TTI-101 | Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Hepatocellular Cancer, Colorectal Cancer, Gastric Adenocarcinoma, Melanoma, Advanced Cancer | 64 | 2024-06-24actual | — | 2025-03-21 |
| Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast CancerNCT05384119Phase 1b: Number of Participants Who Experience a Dose Limiting Toxicity (DLT)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The study was terminated prior to Phase 2 due to slow accrual. | Drug: TTI-101, Palbociclib, Aromatase inhibitor (AI), fulvestrant, ribociclib | Breast Cancer | 6 | 2024-04-25actual | — | 2025-02-21 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19